- Home
- FIG vs BBIO Comparison
FIG vs BBIO Comparison
Compare FIG & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIG | BBIO |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | 1886 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 14.2B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FIG | BBIO |
|---|---|---|
| Price | $18.73 | $69.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 25 |
| Target Price | $50.50 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 14.0M | 2.3M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $31.18 | $89.45 |
| Revenue Next Year | $20.22 | $73.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $16.60 | $31.77 |
| 52 Week High | $114.29 | $84.94 |
Technical Indicators
Market Signals| Indicator | FIG | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 40.28 |
| Support Level | $17.65 | $61.95 |
| Resistance Level | $21.45 | $78.96 |
| Average True Range (ATR) | 1.39 | 3.93 |
| MACD | 0.19 | -0.87 |
| Stochastic Oscillator | 44.43 | 4.38 |
Price Performance
Historical ComparisonAbout FIG Figma Inc.
Figma Inc is engaged in transforming ideas into digital products and experiences. The group focuses on the entire software creation lifecycle, enabling it to quickly launch new products on Figma's browser-based platform and reinforcing its belief that design extends well beyond a single step or role. The company adopts an expansive view, as design is more than how something looks, feels, or works. It derives its revenue from sales of subscriptions for access to its platform.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.